• ABSTRACT
Amid conflicting reports about the link between hormone replacement therapy and breast cancer, the Iowa Women's Health Study gives grounds for cautious optimism. According to the study, women on hormone replacement therapy had a higher incidence of breast cancer, but the excess cancers were of a "favorable" histologic type. This paper discusses clinical decision-making in light of the study results.
CCORDING TO the recently published Iowa Women's Health Study, 1 women receiving hormone replacement therapy may have an increased risk of breast cancer, but in their study, mainly cancers of a "favorable" histologic type-a relatively uncommon category consisting of mucinous, medullary, tubular, or papillary carcinomas. The risk of these types of cancer, which accounted for only 5.4% of the cases of breast cancer in this trial, was approximately twice as high in women who had received hormone replacement therapy for more than 5 years compared with those who had not received it.
This study does not resolve the longstanding controversy about whether hormone replacement therapy causes breast cancer. However, it provides another bit of evidence that should give us cautious optimism about the safety of hormone replacement therapy.
This article looks at the findings of the Iowa Women's Health Study and other studies, examines common themes among the conflicting data, and suggests a reasonable approach for clinicians who want to prescribe hormone replacement pending more definitive data.
• PREVIOUS STUDIES PROVIDE CONFLICTING DATA
Studies have shown that postmenopausal hormone replacement therapy reduces all-cause mortality.
2 -3 However, the data conflict on whether there is a causal link between hormone replacement therapy and breast cancer. Various studies have come to the following divergent conclusions:
• Women receiving hormone replacement for more than 5 years have an increased risk of breast cancer.4-7
• There is no significant increased risk.^-
10
• If women receiving hormone replacement indeed have a higher incidence of breast cancer, the tumors tend to be cancer in situ or cancers with a favorable prognosis.
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• Women who develop breast cancer while on hormone replacement therapy have a more favorable prognosis than women not on hormone replacement therapy, although this effect may wane with time from diagnosis.
ULTRAM (tramadol hydrochloride tablets) BRIEF SUMMARY. CONSULT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION. INDICATIONS AND USAGE
ULTRAM is indicated for the management of moderate to moderately severe pain. CONTRAINDICATIONS ULTRAM should not be administered to patients who have previously demonstrated hypersensitivity to tramadol, any other component of this product or opioids. It is also contraindicated in cases of acute intoxication with alcohol, hypnotics, centrally acting analgesics, opioids or psychotropic drugs. WARNINGS Seizure Risk Seizures have been reported in patients receiving ULTRAM within the recommended dosage range. Spontaneous postmarketing reports indicate that seizure risk is increased with doses of ULTRAM above the recommended range. Concomitant use of ULTRAM increases the seizure risk in patients taking:
• Selective serotonin reuptake inhibitors (SSRI antidepressants or anoretics), • Tricyclic antidepressants (TCAs), and other tricyclic compounds (e.g., cyclobenzaprine, promethazine, etc.), or • Opioids. Administration of ULTRAM may enhance the seizure risk in patients taking:
• MAO inhibitors (see also WARNINGS -Use with MAO Inhibitors), • Neuroleptics, or • Other drugs that reduce the seizure threshold. Risk of convulsions may also increase in patients with epilepsy, those with a history of seizures, or in patients with a recognized risk for seizure (such as head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections). In ULTRAM overdose, naloxone administration may increase the risk of seizure. Anaphylactoid Reactions Serious and rarely fatal anaphylactoid reactions have been reported in patients receiving therapy with ULTRAM. These reactions often occur following the first dose. Other reported reactions include pruritus, hives, bronchospasm, and angioedema. Patients with a history of anaphylactoid reactions to codeine and other opioids may be at increased risk and therefore should not receive ULTRAM (see CONTRAINDICATIONS). Use in Opioid-dependent Patients ULTRAM should not be used in opioid-dependent patients. ULTRAM has been shown to reinitiate physical dependence in some patients that have been previously dependent on other opioids. Consequently, in patients with a tendency to opioid abuse or opioid dependence, treatment with ULTRAM is not recommended. Use with CNS Depressants ULTRAM should be used with caution and in reduced dosages when administered to patients receiving CNS depressants such as alcohol, opioids, anesthetic agents, phenothiazines, tranquilizers or sedative hypnotics. Use with MAO Inhibitors Use ULTRAM with great caution in patients taking monoamine oxidase inhibitors, because animal studies have shown increased deaths with combined administration. PRECAUTIONS Respiratory Depression Administer ULTRAM cautiously in patients at risk for respiratory depression. When large doses of ULTRAM are administered with anesthetic medications or alcohol, respiratory depression may result.Treat such cases as an overdose. If naloxone is to be administered, use cautiously because it may precipitate seizures (see WARNINGS, Seizure Risk and OVERDOSAGE). Increased Intracranial Pressure or Head Trauma ULTRAM should be used with caution in patients with increased intracranial pressure or head injury. Pupillary changes (miosis) from tramadol may obscure the existence, extent, or course of intracranial pathology. Clinicians should also maintain a high index of suspicion for adverse drug reaction when evaluating altered mental status in these patients if they are receiving ULTRAM. Acute Abdominal Conditions The administration of ULTRAM may complicate the clinical assessment of patients with acute abdominal conditions. Withdrawal Withdrawal symptoms may occur if ULTRAM is discontinued abruptly. These symptoms may include: anxiety, sweating, insomnia, rigors, pain, nausea, tremors, diarrhoea, upper respiratory symptoms, piloerection, and rarely hallucinations. Clinical experience suggests that withdrawal symptoms may be relieved by tapering the medication. Patients Physically Dependent on Opioids ULTRAM is not recommended for patients who are dependent on opioids. Patients who have recently taken substantial amounts of opioids may experience withdrawal symptoms. Because of the difficulty in assessing dependence in patients who have previously received substantial amounts of opioid medication, administer ULTRAM cautiously to such patients. Use in Renal and Hepatic Disease Impaired renal function results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. In patients with creatinine clearances of less than 30 mL/min, dosing reduction is recommended (see DOSAGE AND ADMINISTRATION). Metabolism of tramadol and M1 Is reduced in patients with advanced cirrhosis of the liver. In cirrhotic patients, dosing reduction is recommended (see DOSAGE AND ADMINISTRATION). With the prolonged half-life in these conditions, achievement of steady-state is delayed, so that it may take several days for elevated plasma concentrations to develop. Information for Patients • ULTRAM (tramadol hydrochloride tablets) may impair mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
• ULTRAM should not be taken with alcohol containing beverages.
• ULTRAM should be used with caution when taking medications such as tranquilizers, hypnotics or other opiate containing analgesics.
• The patient should be instructed to inform the physician if they are pregnant, think they might become pregnant, or are trying to become pregnant (see PRECAUTIONS: Labor and Delivery).
• The patient should understand the single-dose and 24-hour dose limit and the time interval between doses, since exceeding these recommendations can result in respiratory depression and seizures. Drug Interactions Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data.Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.
Use with Carbamazepine
Concomitant administration of ULTRAM with carbamazepine causes a significant increase in tramadol metabolism, presumably through metabolic induction by carbamazepine. Patients receiving chronic carbamazepine doses of up to 800 mg daily may require up to twice the recommended dose of ULTRAM.
Use with Quinidine
Tramadol is metabolized to M1 by the CYP2D6 P-450 isoenzyme. Quinidine is a selective inhibitor of that Isoenzyme; so that concomitant administration of quinidine and ULTRAM results in increased concentrations of tramadol and reduced concentrations of M1. The clinical consequences of these findings are unknown. In vitro drug interaction studies in human liver microsomes indicate that tramadol has no effect on quinidine metabolism.
Use with Inhibitors of CYP2D6
In vitro drug interaction studies in human liver microsomes indicate that concomitant administration with inhibitors of CYP2D6 such as fluoxetine, paroxetine, and amitriptyline could result in some inhibition of the metabolism of tramadol.
Use with Cimetidine
Concomitant administration of ULTRAM with cimetidine does not result in clinically significant changes in tramadol pharmacokinetics. Therefore, no alteration of the ULTRAM dosage regimen is recommended.
Use with MAO Inhibitors
Interactions with MAO Inhibitors, due to interference with detoxification mechanisms, have been reported for some centrally acting drugs (see WARNINGS, Use with MAO Inhibitors).
Use with Digoxin and Warfarin
Post-marketing surveillance has revealed rare reports of digoxin toxicity and alteration of warfarin effect, including elevation of prothrombin times. Carcinogenesis, Mutagenesis, Impairment of Fertility Tramadol was not mutagenic in the following assays: Ames Salmonella microsomal activation test, CHO/HPRT mammalian cell assay, mouse lymphoma assay (in the absence of metabolic activation), dominant lethal mutation tests in mice, chromosome aberration test in Chinese hamsters, and bone marrow micronucleus tests in mice and Chinese hamsters. Weakly mutagenic results occurred in the presence of metabolic activation in the mouse lymphoma assay and micronucleus test in rats. Overall, the weight of evidence from these tests indicates that tramadol does not pose a genotoxic risk to humans. A slight, but statistically significant, increase in two common murine tumors, pulmonary and hepatic, was observed in a mouse carcinogenicity study, particularly in aged mice (dosing orally up to 30 mg/kg for approximately two years, although the study was not done with the Maximum Tolerated Dose). This finding is not believed to suggest risk in humans. No such finding occurred In a rat carcinogenicity study. No effects on fertility were observed for tramadol at oral dose levels up to 50 mg/kg in male rats and 75 mg/kg in female rats. Pregnancy, Teratogenic Effects: Pregnancy Category C There are no adequate and well-controlled studies in pregnant women. ULTRAM should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Tramadol has been shown to be embryotoxic and fetotoxic in mice, rats and rabbits at maternally toxic doses 3 to 15 times the maximum human dose or higher (120 mg/kg in mice, 25 mg/kg or higher in rats and 75 mg/kg or higher in rabbits), but was not teratogenic at these dose levels. No harm to the fetus due to tramadol was seen at doses that were not maternally toxic. No drug-related teratogenic effects were observed in progeny of mice, rats or rabbits treated with tramadol by various routes (up to 140 mg/kg for mice, 80 mg/kg for rats or 300 mg/kg for rabbits). Embryo and fetal toxicity consisted primarily of decreased fetal weights, skeletal ossification and increased supernumerary ribs at maternally toxic dose levels. Transient delays in developmental or behavioral parameters were also seen In pups from rat dams allowed to deliver. Embryo and fetal lethality were reported only in one rabbit study at 300 mg/kg, a dose that wouId cause extreme maternal toxicity in the rabbit. In peri-and post-natal studies in rats, progeny of dams receiving oral (gavage) dose levels of 50 mg/kg or greater had decreased weights, and pup survival was decreased early in lactation at 80 mg/kg (6 to 10 times the maximum human dose). No toxicity was observed for progeny of dams receiving 8,10,20,25 or 40 mg/kg. Maternal toxicity was observed at all dose levels, but effects on progeny were evident only at higher dose levels where maternal toxicity was more severe. Labor and Delivery ULTRAM should not be used in pregnant women prior to or during labor unless the potential benefits outweigh the risks. Safe use in pregnancy has not been established. Chronic use during pregnancy may lead to physical dependence and post-partum withdrawal symptoms in the newborn. Tramadol has been shown to cross the placenta. The mean ratio of serum tramadol in the umbilical veins compared to maternal veins was 0.83 for 40 women given tramadol during labor. The effect of ULTRAM, if any, on the later growth, development, and functional maturation of the child is unknown. Nursing Mothers ULTRAM is not recommended for obstetrical preoperative medication or for post-delivery analgesia in nursing mothers because its safety in infants and newborns has not been studied. Following a single IV100 mg dose of tramadol, the cumulative excretion in breast milk within 16 hours postdose was 100 pg of tramadol (0.1% of the maternal dose) and 27 pg of M1. Pediatric Use The pediatric use of ULTRAM is not recommended because safety and efficacy in patients under 16 years of age have not been established. Use in the Elderly In subjects over the age of 75 years, serum concentrations are slightly elevated and the elimination half-life is slightly prolonged. The aged also can be expected to vary more widely in their ability to tolerate adverse drug effects. Daily doses in excess of 300 mg are not recommended in patients over 75 (see DOSAGE AND ADMINISTRATION). ADVERSE REACTIONS ULTRAM was administered to 550 patients during the double-blind or open-label extension periods in U.S. studies of chronic nonmalignant pain. Of these patients, 375 were 65 years old or older. Table 1 reports the cumulative incidence rate of adverse reactions by 7,30 and 90 days for the most frequent reactions (5% or more by 7 days). The most frequently reported events were in the central nervous system and gastrointestinal system. Although the reactions listed in the table are felt to be probably related to ULTRAM administration, the reported rates also include some events that may have been due to underlying disease or concomitant medication. The overall incidence rates of adverse experiences in these trials were similar for ULTRAM and the active control groups, TYLENOL® with Codeine #3 (acetaminophen 300 mg with codeine phosphate 30 mg), and aspirin 325 mg with codeine phosphate 30 mg. DRUG ABUSE AND DEPENDENCE ULTRAM has a potential to cause psychic and physical dependences Ihe morphine-type (p-oploid). The drug has been associated with craving, drug-seeking behavior and tolerance development. Cases of abuse and dependence on ULTRAM have been reported. ULTRAM should not be used in opioid-dependent patients. ULTRAM can reinitiate physical dependence in patients that have been previously dependent or chronically using other opioids. In patients with a tendency to drug abuse, a history of drug dependence, or are chronically using opioids, treatment with ULTRAM is not recommended. DOSAGE AND ADMINISTRATION For the treatment of painful conditions, ULTRAM 50 mg to 100 mg can be administered as needed for relief every four to six hours, not to exceed 400 mg per day. For moderate pain, ULTRAM 50 mg may be adequate as the initial dose, and for more severe pain, ULTRAM 100 mg is usually more effective as the initial dose. In a clinical trial, fewer discontinuations due to adverse events, especially dizziness and vertigo, were observed when titrating the dose in increments of 50 mg/day every 3 days until an effective dose (not exceeding 400 mg/day) was reached. Individualization of Dose Available data do not suggest that a dosage adjustment is necessary in elderly patients 65 to 75 years of age unless they also have renal or hepatic impairment. For elderly patients over 75 years old, not more than 300 mg/day in divided doses as above is recommended. In all patients with creatinine clearance less than 30 mL/min, it is recommended that the dosing interval of ULTRAM be increased to 12 hours, with a maximum daily dose of 200 mg. Since only 7% of an administered dose is removed by hemodialysis, dialysis patients can receive their regular dose on the day of dialysis. The recommended dose for patients with cirrhosis is 50 mg every 12 hours. Patients receiving chronic carbamazepine doses up to 800 mg daily may require up to twice the recommended dose of ULTRAM. OVERDOSAGE Cases of overdose with tramadol have been reported. Estimates of ingested dose in foreign fatalities have been in the range of 3 to 5 g. A 3 g intentional overdose by a patient in the clinical studies produced emesis and no sequelae. The lowest dose reported to be associated with fatality was possibly between 500 and 1000 mg in a 40 kg woman, but details of the case are not completely known. Serious potential consequences of overdosage are respiratory depression and seizure. In treating an overdose, primary attention should be given to maintaining adequate ventilation along with general supportive treatment. While naloxone will reverse some, but not all, symptoms caused by overdosage with ULTRAM the risk of seizures is also increased with naloxone administration. In animals convulsions following the administration of toxic doses of tramadol could be suppressed with barbiturates or benzodiazepines but were increased with naloxone. Naloxone administration did not change the lethality of an overdose in mice. Hemodialysis is not expected to be helpful in an overdose because it removes less than 7% of the administered dose in a 4-hour dialysis period.
• THE IOWA WOMEN'S HEALTH STUDY
The Iowa Women's Health Study 1 was designed to examine the effects of several risk factors on the incidence of breast cancer in postmenopausal women.
Methods
In 1985, the investigators mailed a questionnaire to 98,029 women age 55 to 69, who were randomly selected from the Iowa Department of Transportation driver's license list. Those who returned the questionnaire and were not excluded because of premenopausal status or previous mastectomy were entered in the study group (N = 37,105).
Risk factors. The questionnaire included questions about a number of factors associated with breast cancer risk: age, education, alcohol consumption, history of cigarette smoking, personal history of cancer, history of cancer in female relatives (number of relatives and their age at diagnosis were not included), menstrual history, reproductive history, height, current weight, and weight at age 18 (the last three being used to calculate the body mass index). Participants also received a tape measure and instructions on how to measure their hips and waist, from which the investigators calculated the waist-to-hip ratio.
Most important, the questionnaire asked about noncontraceptive hormone use: whether the participant had ever used hormone replacement therapy and for how long (< 5 years or > 5 years) and whether she was currently using hormone replacement therapy and for how long (< 5 years or > 5 years).
Follow-up questionnaires were sent in 1987, 1989, 1992, and 1997 to obtain information on incident self-reported disease and vital status.
Breast cancer cases were identified by checking the Health Registry of Iowa. The investigators coded the tumors according to histology, behavior (eg, in situ vs invasive), and histologic grade.
In 11 years, 1,520 documented cases of breast cancer occurred among the study participants. The investigators divided these cases into four groups:
• Infiltrating ductal or lobular carcinoma, 76.6% • Ductal carcinoma in situ, 11.5%
• Invasive carcinoma of a histologic type with a favorable prognosis (ie, mucinous, medullary, tubular, papillary), 5.4%
• Others (lobular carcinoma in situ or nonepithelial or poorly defined tumors), 6.5%. These were excluded from analysis.
Statistical analysis consisted of calculations of the relative risk erf the first three types of cancer listed above according to the various risk factors, including hormone use.
Results
The results, adjusted for age, showed a statistically significant increase in the risk of developing an invasive carcinoma of favorable histologic type in women who had ever received hormone replacement therapy, compared with women who had never used it. (Keep in mind that this type of tumor accounted for only 5.4% of the cases of breast cancer in the study.) The other tumor types showed a statistically insignificant trend toward an increased risk ( therapy as shown in some previous studies, but they noted an excess of breast cancers of a favorable histologic type. They hinted that hormone use might have a selective biological effect on less aggressive breast tumors. They drew a parallel between their observations and the observation that less aggressive endometrial cancers are seen among estrogen users.
• PROBLEMS WITH THE STUDY
Two potential problems with the study come to mind. Some "favorable" tumors may not be so favorable. Not all experts agree that one of the so-called less aggressive cancers, medullary carcinoma, has a favorable prognosis. [13] [14] [15] Medullary carcinoma accounted for 16 of the 82 "favorable" cases, and if these 16 cases were excluded, the increase in relative risk in this category would be diluted.
What is the absolute risk? The investigators presented their results in terms of relative risk, adjusted for other risk factors. However, the absolute risk may be a more useful number, especially if the complication (eg, cancer of a favorable histologic type) is uncommon. Unfortunately, the report did not divulge the actual numbers of women receiving hormone replacement therapy, nor the percentage of women on therapy who developed breast cancer, compared with those not on therapy. If one quarter of the study patients used hormone replacement therapy, the increase in absolute risk must have been very small, probably less than two excess cases of cancer per 1,000 users.
M RECURRING THEMES FROM THE STUDIES
Among the many studies exploring the link between hormone replacement therapy and breast cancer, we note some repeating themes.
The larger the estrogen dose, the greater the risk. 16 The recent studies that did not show a significant association may reflect the trend to prescribe smaller doses of estrogen in recent years.
The longer the duration of hormone replacement therapy, the greater the risk. Several studies showed this trend.
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The risk increases with age.
5 Knowing this, and considering that the results of the Heart and Estrogen/Progestin Replacement Study 17 raise questions about starting hormone replacement therapy after a coronary event, physicians should be circumspect about starting estrogen in elderly patients and should consider alternatives to indefinite estrogen therapy if bone protection is the sole goal. However, there remains strong evidence of the favorable impact of hormone replacement on all-cause mortality and heart disease when given in an appropriate setting. 
BRIEF SUMMARY-ARTHROTEC® (diclofenac sodium and misoprostol)
Before prescribing, please consult complete prescribing information.
CONTRAINDICATIONS AND WARNINGS ARTHROTEC®, because of the abortifacient property of the misoprostol component, is contraindicated in women who are pregnant. (See PRECAUTIONS.) Reports, primarily from Brazil, of congenital anomalies and reports of fetal death subsequent to misuse of misoprostol alone, as an abortifacient, have been received. Patients must be advised of the abortifacient property and warned not to give the drug to others. ARTHROTEC should not be used in women of childbearing potential unless the patient requires nonsteroidal anti-inflammatory drug (NSAID) therapy and Is at high risk of developing gastric or duodenal ulceration or for developing complications from gastric or duodenal ulcers associated with the use of the NSAID. (See WARNINGS.) In such patients, ARTHROTEC may be prescribed if the patient:
• has had a negative serum pregnancy test within two weeks prior to beginning therapy.
• is capable of complying with effective contraceptive measures.
• has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential should the drug be taken by mistake.
• will begin ARTHROTEC only on the second or third day of the next normal menstrual period. Serious Gl toxicity, such as inflammation, bleeding, ulceration and perforation of the stomach, small intestine or large intestine, can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Remain alert for ulceration and bleeding, even in the absence of previous Gl tract symptoms. Inform patients about the signs and/ or symptoms and the steps to take if they occur. Only 1/5 patients who develop a serious upper Gl adverse event on NSAID therapy is symptomatic. It has been demonstrated that upper Gl ulcers, gross bleeding, or perforation, caused by NSAIDs, appears to occur in approximately 1% of patients treated for 3-6 months, and in 2-4% of patients treated for one year, with an increasing likelihood of developing a serious Gl event during chronic therapy. However, even short-term therapy has risk. Prescribe NSAIDs with extreme caution in those with a prior history of ulcer disease or Gl bleeding. Most spontaneous reports of fatal Gl events are in elderly or debilitated patients and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse event, the lowest effective dose should be used for the shortest possible duration. For very high-risk patients, alternate therapies that do not involve NSAIDs should be considered. Studies have shown that patients with a history of peptic ulcer disease and/or Gl bleeding, and who use NSAIDs, have a greater than 10-fold risk for developing a Gl bleed than patients with neither of these risk factors. In addition to a past history of ulcer disease, pharmacoepidemiological studies have Identified several other conditions or co-therapies that may Increase the risk for Gl bleeding, such as: treatment with oral corticosteroids, treatment with anticoagulants, longer duration of NSAIDtherapy, older age, smoking, alcoholism, poor general health and H. pylori positive status. Hepatic effects: Elevations of liver tests may occur. Borderline elevations (<3x upper limit of normal, or ULN) or greater elevations of transaminases occurred in about 15% of diclofenactreated patients. In clinical trials, meaningful elevations (>3xULN) of AST (SGOT) occurred in about 2% of patients. Meaningful elevations of ALT and/or AST occurred In about 4%, and marked elevations (>8xULN) in about 1%, of patients treated 2-6 months. In an open-label trial, elevated ALT or AST was observed more often in patients receiving diclofenac than other NSAIDs. Postmarketing, rare cases of severe hepatic reactions, including liver necrosis, jaundice, and fulminant fatal hepatitis with and without jaundice have been reported; some underwent liver transplantation. Severe hepatic reactions can occur at any time without a prodrome of distinguishing symptoms. Transaminases should therefore be periodically measured beginning within 4 to 8 weeks after initiating treatment. The misoprostol component does not appear to exacerbate these diclofenac effects. If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur, discontinue ARTHROTEC treatment immediately. Inform patients of the warning signs and symptoms of hepatotoxicity (eg, nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms), and the appropriate action patients should take if these signs and symptoms appear. Anaphylactoid reactions: Anaphylactoid reactions may occur in patients without known prior exposure to ARTHROTEC or its components. ARTHROTEC should not be given to patients with the aspirin triad. The triad typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs. Emergency help should be sought in cases where an anaphylactoid reaction occurs. Advanced renal disease: In patients with advanced kidney disease, treatment with ARTHROTEC is not recommended. PRECAUTIONS General: ARTHROTEC cannot be used to substitute for corticosteroids or to treat for corticosteroid insufficiency. ARTHRO-TEC's anti-inflammatory activity may diminish the utility of this diagnostic sign.
INDICATIONS AND USAGE
Renal effects: Use caution when initiating ARTHROTEC in dehydrated patients. Rehydrate patients first. Also use caution in patients with kidney disease (see WARNINGS-Advanced renal <s> disease). Long-term administration of diclofenac has resulted in renal papillary necrosis and other renal medullary changes. Patients with impaired renal function, heart failure, or liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly are at greatest risk of renal decompensation. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. Diclofenac metabolites are eliminated primarily by the kidneys and patients with significantly impaired renal function should be more closely monitored. Hematologic effects: Anemia may occur; it may be due to fluid retention, Gl blood loss, or an incompletely described effect upon erythropoiesis. Patients should have their hemoglobin or hematocrit checked if they exhibit signs or symptoms of anemia. ARTHROTEC may interfere to some extent with platelet function and vascular responses to bleeding. Patients with coagulation disorders or receiving anticoagulants should be carefully monitored. Aseptic meningitis:
Aseptic meningitis with fever and coma has been observed on rare occasions in patients on diclofenac. Fluid retention and edema: Fluid retention and edema may occur. Use with caution in patients with a history of cardiac decompensation, hypertension, or other conditions predisposing to fluid retention. Preexisting asthma: Do not use in patients with aspirin-sensitive asthma because of the risk of severe fatal bronchospasm. Use with caution in patients with preexisting asthma. Porphyria: Use in patients with hepatic porphyria should be avoided. Laboratory tests: Patients should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (eg, eosinophilia, rash, etc) or if abnormal liver tests persist or worsen, discontinue ARTHROTEC. Drug interactions: ARTHROTEC may increase the serum levels of digoxin, methotrexate, lithium and phénobarbital; patients should be monitored for toxicity. ARTHROTEC may increase cyclosporine nephrotoxicity, exacerbate Gl bleeding in patients on warfarin, and inhibit the activity of antihypertensives and diuretics. Use caution in administering ARTHROTEC with any of these agents, particularly if renal function is impaired. Aspirin may diminish the therapeutic effect of diclofenac and coadministration is not recommended. Diclofenac Na may alter a diabetic patient's response to insulin or oral hypoglycemic agents. Antacids containing magnesium may exacerbate diarrhea and should not be coadministered with ARTHROTEC. Animal toxicology: A reversible increase in the number of normal surface gastric epithelial cells occurred in the dog, rat, and mouse during long-term toxicology studies with misoprostol. An apparent response of the female mouse to misoprostol in long-term studies at 100-1000 x the human dose was hyperostosis, mainly of the medulla of sternebrae. These effects have not been seen in human studies. Carcinogenesis, mutagenesis, impairment of fertility: Animal studies to evaluate the potential for carcinogenesis and effects on fertility have been performed with each component of ARTH-ROTEC given alone. ARTHROTEC itself was not genotoxic in the AMES test, the Chinese hamster ovary cell (CHO/HGPRT) forward mutation test, the rat lymphocyte chromosome aberration test or the mouse micronucleus test. In a 24-mo rat carcinogenicity study, oral misoprostol at doses up to 24x the recommended maximum human dose of 0.6 mg/m 2 /day was not tumorigenic. In a 21-mo mouse carcinogenicity study, oral misoprostol at doses up to 80x the recommended maximum human dose was not tumorigenic. Misoprostol, when administered to male and female breeding rats in an oral dose-range of 1-100x the recommended maximum human dose produced dose-related pre-and post-Implantation losses and a significant decrease in the number of live pups born at the highest dose. These findings suggest the possibility of a general adverse effect on fertility in males and females. In a 24-mo rat carcinogenicity study, oral diclofenac Na was not tumorigenic at 0.08x the recommended maximum human dose of 148 mg/m 2 /day. In a 24-mo mouse carcinogenicity study, oral diclofenac Na at doses up to 0.006x the recommended maximum human dose in males and 0.02x the recommended maximum human dose in females was not tumorigenic. Diclofenac Na at oral doses up to 0.16x the recommended maximum human dose was found to have no effect on fertility and reproductive performance of male and female rats. Pregnancy: Pregnancy category X: See boxed CONTRAINDI-CATIONS AND WARNINGS regarding misoprostol. ARTHRO-TEC is contraindicated in pregnancy. Non-teratogenic effects: Misoprostol may endanger pregnancy (may cause miscarriage) and thereby cause harm to the fetus when administered to a pregnant woman. Misoprostol produces uterine contractions, uterine bleeding, and expulsion of the products of conception. Miscarriages caused by misoprostol may be incomplete. In studies in women undergoing elective termination of pregnancy during the first trimester, misoprostol caused partial or complete expulsion of the products of conception in 11% of the subjects and increased uterine bleeding in 41%. Reports, primarily from Brazil, of congenital anomalies and reports of fetal death subsequent to misuse of misoprostol alone, as an abortifacient, have been received (see CONTRAINDICATIONS AND WARNINGS). If a woman is or becomes pregnant while taking this drug, the drug should be discontinued and the patient apprised of the potential hazard to the fetus. The diclofenac Na component of ARTHROTEC, like other NSAIDs which are prostaglandin-inhibiting drugs, may affect the fetal cardiovascular system causing premature closure of the ductus arteriosus. NSAIDs may also inhibit uterine contractions. Teratogenic effects: Animal tests have revealed no evidence of teratogenic potential for ARTHROTEC, misoprostol, or diclofenac. Nursing mothers: Because of the potential for serious adverse reactions in nursing infants, ARTHROTEC is not recommended for use by nursing mothers. Pediatric use: Safety and effectiveness in pediatric patients have not been established. Geriatric use: In clinical trial patients >65 years of age, no overall differences were observed between efficacy, adverse events or PK profiles of older and younger patients. However, the elderly are likely to tolerate adverse events less well than younger patients. ADVERSE REACTIONS Adverse reactions associated with ARTHROTEC Gastrointestinal: In clinical trials, the most frequently reported adverse events were Gl disorders: abdominal pain (21%), diarrhea (19%), dyspepsia (14%), nausea (11%), and flatulence (9%). ARTHROTEC can cause more Gl symptoms than diclofenac alone. These events led to discontinuation of therapy in 9% of patients. Diarrhea and abdominal pain developed early in the course of therapy, and were usually self-limited (resolved after 2 to 7 days). Rare instances of profound diarrhea leading to severe dehydration have been reported in patients receiving misoprostol. Patients with an underlying condition such as inflammatory bowel disease, or those in whom dehydration, were it to occur, would be dangerous, should be monitored carefully. The incidence of diarrhea can be minimized by administering ARTHROTEC with food and by avoiding coadministration with magnesium-containing antacids. Gynecological: Postmenopausal vaginal bleeding may occur (see below) and should be evaluated to rule out gynecologic pathology. Other: Adverse experiences reported occasionally or rarely with ARTHROTEC, diclofenac or other NSAIDs, or misoprostol are: Body as a whole: Asthenia, death, fatigue, fever, infection, malaise, sepsis. Cardiovascular system: Arrhythmia, atrial fibrillation, CHF, hypertension, hypotension, increased CPK, increased LDH, Ml, palpitations, phlebitis, PVCs, syncope, tachycardia, vasculitis. Central and peripheral nervous system: Coma, convulsions, dizziness, drowsiness, headache, hyperesthesia, hypertonia, hypoesthesia, insomnia, meningitis, migraine, neuralgia, paresthesia, somnolence, tremor, vertigo.
Digestive:
Anorexia, appetite changes, constipation, dry mouth, dysphagia, enteritis, esophageal ulceration, esophagitis, eructation, gastritis, gastroesophageal reflux, Gl bleeding, Gl neoplasm benign, glossitis, heartburn, hematemesis, hemorrhoids, intestinal perforation, peptic ulcer, stomatitis and ulcerative stomatitis, tenesmus, vomiting. Female reproductive disorders:
Breast pain, dysmenorrhea, intermenstrual bleeding, leukorrhea, menstrual disorder, menorrhagia, vaginal hemorrhage. Hemic and lymphatic system: Agranulocytosis, anemia, aplastic anemia, coagulation time increased, ecchymosis, eosinophilia, eplstaxis, hemolytic anemia, leukocytosis, leukopenia, lymphadenopathy, melena, pancytopenia, pulmonary embolism, purpura, rectal bleeding, thrombocythemia, thrombocytopenia. Hypersensitivity:
Angioedema, laryngeal/ pharyngeal edema, urticaria. Liver and biliary system:
Abnormal hepatic function, bilirubinemia, hepatitis, jaundice, liver failure, pancreatitis. Male reproductive disorders: Impotence, perineal pain. Metabolic and nutritional:
Alkaline phosphatase increased, BUN increased, dehydration, glycosuria, gout, hypercholesterolemia, hyperglycemia, hyperuricemia, hypoglycemia, hyponatremia, periorbital edema, porphyria, weight changes. Musculoskeletal system: Arthralgia, myalgia. Psychiatric: Anxiety, concentration impaired, confusion, depression, disorientation, dream abnormalities, hallucinations, irritability, nervousness, paranoia, psychotic reaction. Respiratory system: Asthma, coughing, dyspnea, hyperventilation, pneumonia, respiratory depression. Skin and appendages:
Acne, alopecia, bruising, eczema, erythema multiforme, exfoliative dermatitis, pemphigoid reaction, photosensitivity, pruritus, pruritus ani, rash, skin ulceration, Stevens-Johnson syndrome, sweating increased, toxic epidermal necrolysis. Special senses: Hearing impairment, taste loss, taste perversion, tinnitus. Urinary system: Cystitis, dysuria, hematuria, interstitial nephritis, micturition frequency, nocturia, nephrotic syndrome, oliguria/polyuria, papillary necrosis, proteinuria, renal failure, urinary tract infection. Vision: Amblyopia, blurred vision, conjunctivitis, diplopia, glaucoma, iritis, lacrimation abnormal, night blindness, vision abnormal. OVERDOSAGE The toxic dose of ARTHROTEC has not been determined. However, signs of overdosage from the components of the product may include: diclofenacGl complaints, confusion, drowsiness or general hypotonia; misoprostolsedation, tremor, convulsions, dyspnea, abdominal pain, diarrhea, fever, palpitations, hypotension, or bradycardia. Overdosage symptoms should be treated with supportive therapy. In case of acute overdosage, gastric lavage is recommended. Induced diuresis may be beneficial. The use of oral activated charcoal may help to reduce absorption. DOSAGE AND ADMINISTRATION ARTHROTEC is administered as ARTHROTEC 50 (50 mg diclofenac Na/200 meg misoprostol) or as ARTHROTEC 75 (75 mg diclofenac Na/200 meg misoprostol). OA;The recommended dosage for maximal Gl mucosal protection is ARTHROTEC 50 tid. RA: The recommended dosage is ARTHROTEC 50 tid or qid. For OA and RA patients who experience intolerance, ARTHRO-TEC 75 bid or ARTHROTEC 50 bid can be used, but are less effective in preventing ulcers. ARTHROTEC fixed dose combination is not appropriate for patients who would not receive the appropriate dose of both ingredients. Doses of the components delivered with these regimens are as follows: SPECIAL DOSING CONSIDERATIONS: ARTHROTEC contains misoprostol, which provides protection against gastric and duodenal ulcers. For gastric ulcer prevention, the 200 meg qid and tid regimens are therapeutically equivalent, but more protective than the bid regimen. For duodenal ulcer prevention, the qid regimen is more protective than the tid or bid regimens. However, the qid regimen is less well tolerated than the tid regimen because of usually self-limited diarrhea related to the misoprostol dose (see ADVERSE REACTIONS-Gastrointestinal) , and the bid regimen may be better tolerated than tid in some patients. Dosages may be individualized using the separate products (misoprostol and diclofenac), after which the patient may be changed to the appropriate ARTHROTEC dose, if clinically indicated, misoprostol co-therapy with ARTHROTEC, or use of the individual components to optimize the misoprostol dose and/or frequency of administration, may be appropriate. The total dose of misoprostol should not exceed 800 meg/day, and no more than 200 meg of misoprostol should be administered at any one time. Doses of diclofenac higher than 150 mg/day in OA or higher than 225 mg/day in RA are not recommended. 
• TAILORING THERAPY TO THE INDIVIDUAL
Although the risk may be small, we should not dismiss it: any increase in the incidence of breast cancer must be viewed as an adverse effect of hormone replacement therapy. Our challenge is to tailor hormone replacement therapy so that each patient receives the maximum possible benefit with the least possible risk.
In doing so, our clinical decisions will be influenced by evolving knowledge on several fronts. Issues about hormone replacement and breast disease (as well as its effects on the heart and bones) may be better clarified by results of the Women's Health Initiative studies in progress. Selective estrogen receptor modulators such as raloxifene may present an alternative to estrogen replacement for patients with a high risk of breast cancer who have no vasomotor symptoms, are at average or low risk for heart disease, but are at risk for osteoporosis. 18 In the meantime, given the caveats noted above, the current study does give us cautious optimism about prescribing hormone replacement therapy. E3
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